CJC-1295, single vial

Growth hormone-releasing hormone (GHRH) analogue

CJC-1295

Growth hormone-releasing hormone (GHRH) analogue. Supplied for laboratory research use only.

  • GHRH analogue; reached Phase 2 for HIV lipodystrophy, halted 2006
  • Never approved; FDA Category 2 restricted bulk substance
  • Named in April 2026 warning letter over sterility violations
  • Supplied for laboratory research use only. Not for human or veterinary use.
$239.99$359.97 Save 33%
Choose your supply
Most Popular
Best Value
In stock, ready to ship

90-Day Money-Back Guarantee

Every order is covered for ninety days from delivery. If you decide against it inside that window, contact us and we will refund the purchase price.

Research use only. Not for human or veterinary use or consumption. This product is not approved by the FDA and is not intended to diagnose, treat, cure or prevent any disease.

What it is
CompoundCJC-1295, also designated Modified GRF (1-29) is a related but distinct non-DAC variant
ClassGrowth hormone-releasing hormone (GHRH) analogue
FormLyophilised powder, supplied in a vial
OriginatorNot stated
Development status

CJC-1295 is an investigational compound and is not approved by the FDA for any indication. It is in Phase 2 clinical trials.

Not approved anywhere. Reached Phase 2 for HIV-associated lipodystrophy before that trial was halted in 2006; no active approval pathway. FDA placed CJC-1295 on its Category 2 bulk drug substances list, which bars licensed US compounding pharmacies from compounding it regardless of prescription.

Shipping & returns
ReturnsNinety days from delivery. Contact us and we will refund the purchase price.
CJC-1295 $239.99

The specifics

The details, if you want them.

ClassGHRH (growth hormone-releasing hormone) analogue
Amino acids29
Half-lifeapproximately 8 days (DAC form); the non-DAC Mod GRF 1-29 variant has a much shorter half-life
Trial phasePhase 2 (discontinued, 2006)
FormLyophilised powder
Receptor target(s)GHRH receptor
Binding mechanismDrug Affinity Complex (DAC) — a maleimidopropionic acid-based linker that binds covalently to serum albumin, extending half-life; the non-DAC variant lacks this modification entirely

Development

Where it is up to.

Reached Phase 2 for one indication (HIV-associated lipodystrophy) before that trial was halted in 2006. No result from that trial is presented here.

Questions

The questions people actually ask.

What is CJC-1295?
A synthetic peptide, a GHRH analogue. Note: the long-acting 'DAC' form and the shorter-acting Mod GRF 1-29 variant are chemically distinct products sometimes sold under the same name.
Is CJC-1295 approved by the FDA?
No. It has never been approved for any indication and is on FDA's Category 2 restricted list, which bars compounding pharmacies from using it.
What does "Research Use Only" mean?
Research Use Only means exactly that: intended for laboratory and research settings only, not for human or animal use, consumption, diagnosis, treatment, cure, or prevention of any disease.
How is CJC-1295 supplied?
As a vial of lyophilised (freeze-dried) powder, sold for laboratory and research use only.
What is your refund policy?
Ninety days from delivery. If you decide against it inside that window, contact hello@getmrpeps.com and we will refund the purchase price. Damaged or incorrect orders are replaced or refunded regardless.